After 9 months of pharmaceutical care implementation , the test group showed a significant decline in systolic and diastolic blood pressure ( p = 0.0001 ) , serum phosphorus level ( p = 0.006 ) and parathyroid hormone level ( p = 0.001 ) versus their baseline values and versus the control .